A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Zhao, Wanhong; Liu, Jie; Wang, Baiyan; Chen, Yinxia; Cao, Xing-Mei; Yang, Yun; Zhang, Yilin; Wang, Fangxia; Zhang, Pengyu; Lei, Bo; Gu, Liufang; Wang, Jianli; Yang, Nan; Zhang, Ru; Zhang, Hui; Shen, Ying; Bai, Ju; Xu, Yan; Wang, Xugeng; Zhang, Ruili; Wei, Lili; Li, Zongfang; Li, Zhenzhen; Geng, Yan; He, Qian; Zhuang, Qiu-Chuan; Fan, Xiao-Hu; He, Aili; Zhang, Wanggang

doi:10.1186/s13045-018-0681-6

Public

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

Published in Journal of Hematology & Oncology • Dec 1, 2018

Authors:

Wanhong Zhao

Jie Liu

Baiyan Wang

Abstract

BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relap...

Subject

Medicine

Internal medicine

Leukopenia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!